JP2013545744A5 - - Google Patents

Download PDF

Info

Publication number
JP2013545744A5
JP2013545744A5 JP2013538312A JP2013538312A JP2013545744A5 JP 2013545744 A5 JP2013545744 A5 JP 2013545744A5 JP 2013538312 A JP2013538312 A JP 2013538312A JP 2013538312 A JP2013538312 A JP 2013538312A JP 2013545744 A5 JP2013545744 A5 JP 2013545744A5
Authority
JP
Japan
Prior art keywords
dimethoxyphenyl
benzyl
methyl
piperidin
pyrrolidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013538312A
Other languages
English (en)
Japanese (ja)
Other versions
JP5847830B2 (ja
JP2013545744A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2011/054993 external-priority patent/WO2012063207A1/en
Publication of JP2013545744A publication Critical patent/JP2013545744A/ja
Publication of JP2013545744A5 publication Critical patent/JP2013545744A5/ja
Application granted granted Critical
Publication of JP5847830B2 publication Critical patent/JP5847830B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013538312A 2010-11-10 2011-11-09 オレキシン受容体拮抗薬として有用なラクタム誘導体 Expired - Fee Related JP5847830B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2010055105 2010-11-10
IBPCT/IB2010/055105 2010-11-10
PCT/IB2011/054993 WO2012063207A1 (en) 2010-11-10 2011-11-09 Lactam derivatives useful as orexin receptor antagonists

Publications (3)

Publication Number Publication Date
JP2013545744A JP2013545744A (ja) 2013-12-26
JP2013545744A5 true JP2013545744A5 (enExample) 2014-12-11
JP5847830B2 JP5847830B2 (ja) 2016-01-27

Family

ID=45757741

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013538312A Expired - Fee Related JP5847830B2 (ja) 2010-11-10 2011-11-09 オレキシン受容体拮抗薬として有用なラクタム誘導体

Country Status (6)

Country Link
US (1) US9242970B2 (enExample)
EP (1) EP2638008B1 (enExample)
JP (1) JP5847830B2 (enExample)
CN (1) CN103201261A (enExample)
CA (1) CA2815179A1 (enExample)
WO (1) WO2012063207A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
KR101995683B1 (ko) 2012-06-04 2019-07-02 이도르시아 파마슈티컬스 리미티드 벤즈이미다졸-프롤린 유도체
HUE042374T2 (hu) 2012-06-13 2019-06-28 Incyte Holdings Corp Szubsztituált triciklusos vegyületek mint FGFR inhibitorok
CN107802623B (zh) * 2012-07-19 2020-10-30 开曼化学股份有限公司 用于ep4介导的骨相关疾病和病症的二氟内酰胺组合物
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
EP3763367A1 (en) 2012-12-06 2021-01-13 Celgene Quanticel Research, Inc. Pyridine-pyrazole derivatives as histone demethylase inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
BR112015023080A2 (pt) 2013-03-15 2017-07-18 Cayman Chemical Co Inc composto, composição farmacêutica, e, método para tratamento de doenças
WO2014144610A1 (en) 2013-03-15 2014-09-18 Cayman Chemical Company, Inc. Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
JP6368351B2 (ja) 2013-03-15 2018-08-01 ケイマン ケミカル カンパニー, インコーポレーテッド ジフルオロラクタムアナログを合成する方法
HUE036571T2 (hu) 2013-04-19 2018-07-30 Incyte Holdings Corp Biciklusos heterociklusok mint FGFR inhibitorok
CN104133004A (zh) * 2013-05-03 2014-11-05 上海美迪西生物医药有限公司 血浆样品中2,3-吲哚醌的浓度的测定方法
WO2015009991A2 (en) 2013-07-19 2015-01-22 Cayman Chemical Company, Inc. Methods, systems, and compositions for promoting bone growth
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
US9914720B2 (en) 2013-12-03 2018-03-13 Idorsia Pharmaceuticals Ltd Crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[D]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
HK1225734B (en) 2013-12-04 2017-09-15 Idorsia Pharmaceuticals Ltd Use of benzimidazole-proline derivatives
US9975876B2 (en) 2013-12-09 2018-05-22 Merck Sharp & Dohme Corp. 2-pyridyloxy-3-ester-4-ether orexin receptor antagonists
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MX388991B (es) 2015-02-20 2025-03-20 Incyte Corp Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr)
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2017223243A1 (en) * 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
JP7054529B2 (ja) 2016-06-21 2022-04-14 エックス4 ファーマシューティカルズ, インコーポレイテッド Cxcr4阻害剤およびその使用
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
ES2912657T3 (es) * 2017-08-02 2022-05-26 Vertex Pharma Procesos para preparar compuestos de pirrolidina
EP3788047B1 (en) 2018-05-04 2024-09-04 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
BR112020022373A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation sais de um inibidor de fgfr
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN110563565A (zh) * 2019-09-02 2019-12-13 南通大学 一种3-溴-6-氟-2-甲氧基苯甲醛的合成方法
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
KR20220100879A (ko) 2019-10-14 2022-07-18 인사이트 코포레이션 Fgfr 저해제로서의 이환식 헤테로사이클
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
KR20220131900A (ko) 2019-12-04 2022-09-29 인사이트 코포레이션 Fgfr 억제제의 유도체
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
TW202313611A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為fgfr抑制劑之三環雜環
EP4352060A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CN114456184B (zh) * 2022-02-21 2023-08-22 南华大学附属第一医院 一种3-芳基异喹啉衍生物及其制备与应用
CN115047127B (zh) * 2022-04-25 2024-03-08 中国检验检疫科学研究院 一种利用挥发性代谢组学技术鉴别nfc和fc橙汁的方法
TW202409023A (zh) 2022-07-14 2024-03-01 美商富曼西公司 除草苯并𠯤
WO2025111184A1 (en) 2023-11-21 2025-05-30 Fmc Corporation Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides
WO2025224168A1 (en) 2024-04-24 2025-10-30 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115862D0 (en) * 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
JP2006501201A (ja) * 2002-07-23 2006-01-12 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
CA2557163C (en) 2004-03-01 2011-08-16 Actelion Pharmaceuticals Ltd Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
JP2008542276A (ja) * 2005-05-23 2008-11-27 メルク エンド カムパニー インコーポレーテッド プロリンビスアミドオレキシン受容体アンタゴニスト
KR101065239B1 (ko) 2006-03-15 2011-09-16 액테리온 파마슈티칼 리미티드 기억 기능을 증진하는 테트라히드로이소퀴놀린 유도체
CA2659299A1 (en) * 2006-08-15 2008-02-21 Actelion Pharmaceuticals Ltd Azetidine compounds
DE602007009284D1 (de) * 2006-09-29 2010-10-28 Actelion Pharmaceuticals Ltd 3-aza-bicycloä3.1.0ühexanderivate
CL2008000836A1 (es) * 2007-03-26 2008-11-07 Actelion Pharmaceuticals Ltd Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
EP2176258A1 (en) * 2007-07-03 2010-04-21 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
RU2010109455A (ru) * 2007-08-15 2011-09-20 Актелион Фармасьютиклз Лтд (Ch) Производные 1,2-диамидоэтилена в качестве антагонистов орексина
CN101874030B (zh) * 2007-09-24 2012-11-14 埃科特莱茵药品有限公司 用作食欲素受体拮抗剂的吡咯烷和哌啶
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
CN102015645B (zh) * 2008-04-30 2012-11-14 埃科特莱茵药品有限公司 哌啶和吡咯烷化合物
JP2011522878A (ja) * 2008-06-11 2011-08-04 アクテリオン ファーマシューティカルズ リミテッド オレキシン受容体拮抗薬としてのテトラゾール化合物
JP2012506377A (ja) * 2008-10-21 2012-03-15 メルク・シャープ・エンド・ドーム・コーポレイション 2,4−二置換フェニルカルボキサミド・オレキシン受容体アンタゴニスト
EP2429523A1 (en) 2009-05-12 2012-03-21 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one and [1,3]-thiazinan-4-one compounds as orexin receptor antagonists
EP2430004B1 (en) 2009-05-12 2013-07-17 Actelion Pharmaceuticals Ltd. Novel oxazolidinone derivatives and their use as orexin receptor antagonists

Similar Documents

Publication Publication Date Title
JP2013545744A5 (enExample)
IL258577A (en) 2,4-dihydroxy-nicotinamides as apj agonists
JP2018530591A5 (enExample)
RU2396269C2 (ru) Производные гетероарилзамещенного пиперидина в качестве ингибиторов печеночной карнитин пальмитоилтрансферазы (l-cpt1)
RU2010137300A (ru) Модуляторы бета-амилоида
JP2011503166A5 (enExample)
RU2012105284A (ru) Спиро-аминосоединения, пригодные для лечения нарушений сна и лекарственного привыкания
ME02437B (me) Disupstituirani oktahidropirolo[3,4-c]piroli kao modulatori oreksin receptora
JP2016145215A5 (enExample)
JP2007523208A5 (enExample)
HRP20250632T1 (hr) Nlrp3 inhibitori
JP2013515032A5 (enExample)
IL187690A (en) Derivatives 1, 2, 4 - Triazolo - 1, 6 - Naphthiridines as inhibitors of AKT activity for use in the preparation of drugs for the treatment of cancer
JP2013544873A5 (enExample)
HRP20120281T1 (hr) Derivati azabiciklo[3.1.0]heksana, korisni kao modulatori dopaminskih receptora d3
RU2009121564A (ru) Азаадамантановые производные и способы применения
RU2015132181A (ru) Фтор-[1,3]-оксазины в качестве ингибиторов васе1
JP2006506352A5 (enExample)
JP2015521999A5 (enExample)
JP2013508403A5 (enExample)
JP2013539777A5 (enExample)
JP2014516073A5 (enExample)
JP2020516671A5 (enExample)
JP2017502049A5 (enExample)
CA2642922A1 (en) Melanocortin type 4 receptor agonist piperidinoylpyrrolidines